Qiming Corporate GP VI, Ltd. sold $5.9M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 217,512 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $27.35 ($26.34–$28.44, $5.95M total) across 16 trades over 2026-10-19 to 2026-10-20. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Original reporting
SEC EDGAR · Qiming Corporate GP VI, Ltd., Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, Qiming Venture Partners VIII-HC, L.P.
Published Oct 21, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMR
Bearish
medium confidence
Mentioned
$ALMR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMRBearishLow
01

Why it matters

The disclosed sale may prompt short sellers and could slightly depress the stock in the short term.

02

Market read

A modest insider sell that could generate brief downward pressure on ALMR.

03

What to watch

Potential upcoming clinical data releases or financing needs not disclosed in the filing.

Relevance 6/10Novelty 4/10Timing: after-market today

Background

Form 4 filings disclose insider transactions; Qiming Corporate GP VI is a 10% owner of ALMR.

Company-level read

Ticker impact

$ALMRBearishMedium confidence
Context

Qiming Corporate GP VI sold $5.9M of ALMR shares, reducing its indirect holding to 1.85M shares.

Expected impact

likely downward pressure as the market prices in the insider sell.

Evidence & confidence

A 10% owner sold 217,512 shares at $27.35 average, a material stake reduction that can be interpreted as reduced confidence.

Market effects

Minimal impact on the broader biotech sector; only a single insider transaction.

No regional effect beyond the company's share price.

Limited to investors tracking insider activity in small-cap biotech.

Counterpoint

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Alamar Biosciences, Inc.

    Biotech firm whose shares were sold.

  • Qiming Corporate GP VI, Ltd.

    10% owner reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue growth of 68% YoY, with consumables up 79%. Gross margin improved to 61.5%. The company raised full-year guidance and announced partnerships with U.K. Biobank and GSK, totaling over 140,000 samples. ALMR added 35 publications, bringing the total to over 200, and strengthened its leadership team.

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with gross margin at 61.5%. Net loss was $13.3M. Full-year revenue guidance raised to $121M-$123M. Company finalized large-scale studies with UK Biobank and GSK, focusing on neurodegenerative and inflammatory diseases. Cash position at $231.5M supports expansion plans. President Todd White to retire by year-end.

$ALMRMed

Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68%

Alamar Biosciences Inc (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with consumables revenue representing 53% of total revenue. Gross margin reached 61.5%. Full-year guidance was raised to $121-123M. Net loss widened to $13.3M. The company secured partnerships with UK Biobank and GSK. Q4 revenue guidance implies flat sequential growth, raising concerns about near-term momentum.

$ALMRMed

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o